LEXX vs. ADAP, SKYE, IKNA, CLSD, ONCY, MCRB, PYRGF, ANEB, MNOV, and IMMX
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Adaptimmune Therapeutics (ADAP), Skye Bioscience (SKYE), Ikena Oncology (IKNA), Clearside Biomedical (CLSD), Oncolytics Biotech (ONCY), Seres Therapeutics (MCRB), PyroGenesis Canada (PYRGF), Anebulo Pharmaceuticals (ANEB), MediciNova (MNOV), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.
Lexaria Bioscience vs. Its Competitors
Adaptimmune Therapeutics (NASDAQ:ADAP) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.
Adaptimmune Therapeutics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
In the previous week, Adaptimmune Therapeutics had 7 more articles in the media than Lexaria Bioscience. MarketBeat recorded 8 mentions for Adaptimmune Therapeutics and 1 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.62 beat Adaptimmune Therapeutics' score of 0.20 indicating that Lexaria Bioscience is being referred to more favorably in the news media.
31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 12.7% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Adaptimmune Therapeutics has a net margin of -38.91% compared to Lexaria Bioscience's net margin of -1,784.03%. Lexaria Bioscience's return on equity of -111.84% beat Adaptimmune Therapeutics' return on equity.
Adaptimmune Therapeutics currently has a consensus price target of $1.35, suggesting a potential upside of 463.90%. Lexaria Bioscience has a consensus price target of $7.00, suggesting a potential upside of 704.60%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Adaptimmune Therapeutics.
Lexaria Bioscience has lower revenue, but higher earnings than Adaptimmune Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Adaptimmune Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Adaptimmune Therapeutics beats Lexaria Bioscience on 9 of the 16 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:LEXX) was last updated on 6/30/2025 by MarketBeat.com Staff
